Delivering Unprecedented Access to Biosimilars in Global Markets
  • Developing, Manufacturing and Commercializing
    Biosimilar Products for Global Markets
Who We Are

Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Epirus’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Learn More

News & Events

July 15, 2014

EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)

July 15, 2014

Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors

Bookmark and Share